L. Fluellen

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.

P. Rose, N. Fusco, L. Fluellen, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

C. Hoppel, P. Rose, S. Ingalls, 2000, Gynecologic oncology.

Tolerance of twenty-four hour paclitaxel and carboplatin as first-line therapy in ovarian, peritoneal and fallopian tube carcinoma.

P. Rose, N. Fusco, L. Fluellen, 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.

P. Rose, I. Horowitz, W. Mcguire, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.